Cellectis Reports Q1 2025 Financial Results and Strategic Developments

Cellectis SA ( (CLLS) ) has issued an announcement.

On May 12, 2025, Cellectis reported its financial results for the first quarter of 2025, revealing a cash position of $246 million as of March 31, 2025, which is expected to support operations into the second half of 2027. The company highlighted ongoing progress in its UCART22 and UCART20x22 clinical trials and its research collaboration with AstraZeneca. Despite a $23.8 million increase in net loss compared to the previous year, Cellectis remains focused on advancing its core programs and presenting novel research at the upcoming ASGCT annual meeting.

The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.

Spark’s Take on CLLS Stock

According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.

Cellectis SA’s stock score is influenced by its strong strategic collaborations, notably with AstraZeneca, which enhance its financial stability and extend its cash runway. However, the company’s ongoing challenges with profitability and mixed technical signals weigh down the overall score. The positive earnings call sentiment and future clinical trial advancements are significant positives, whereas current valuation metrics and profitability issues are key concerns.

To see Spark’s full report on CLLS stock, click here.

More about Cellectis SA

Cellectis S.A. is a clinical-stage biotechnology company that utilizes its pioneering gene editing platform to develop cell and gene therapies. The company focuses on creating life-saving treatments, particularly through its UCART clinical programs and strategic partnerships, such as with AstraZeneca.

Average Trading Volume: 343,625

Technical Sentiment Signal: Sell

Current Market Cap: $112.5M

See more data about CLLS stock on TipRanks’ Stock Analysis page.